| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO, Director | C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO | /s/ James R. Oehler, Attorney-in-Fact | 03 Oct 2025 | 0001528185 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HALO | Common Stock | Options Exercise | $162K | +20K | +2.73% | $8.11 | 754K | 01 Oct 2025 | Direct | F1 |
| transaction | HALO | Common Stock | Sale | -$879K | -11.7K | -1.55% | $75.11 | 742K | 01 Oct 2025 | Direct | F1, F2 |
| transaction | HALO | Common Stock | Sale | -$628K | -8.3K | -1.12% | $75.69 | 734K | 01 Oct 2025 | Direct | F1, F3 |
| transaction | HALO | Common Stock | Options Exercise | $162K | +20K | +2.73% | $8.11 | 754K | 02 Oct 2025 | Direct | F1 |
| transaction | HALO | Common Stock | Sale | -$465K | -6.6K | -0.88% | $70.51 | 747K | 02 Oct 2025 | Direct | F1, F4 |
| transaction | HALO | Common Stock | Sale | -$727K | -10.2K | -1.37% | $71.28 | 737K | 02 Oct 2025 | Direct | F1, F5 |
| transaction | HALO | Common Stock | Sale | -$173K | -2.4K | -0.33% | $72.07 | 735K | 02 Oct 2025 | Direct | F1, F6 |
| transaction | HALO | Common Stock | Sale | -$51.3K | -700 | -0.1% | $73.24 | 734K | 02 Oct 2025 | Direct | F1, F7 |
| transaction | HALO | Common Stock | Sale | -$7.47K | -100 | -0.01% | $74.67 | 734K | 02 Oct 2025 | Direct | F1, F8 |
| transaction | HALO | Common Stock | Options Exercise | $162K | +20K | +2.73% | $8.11 | 754K | 03 Oct 2025 | Direct | F1 |
| transaction | HALO | Common Stock | Sale | -$975K | -14.2K | -1.89% | $68.47 | 739K | 03 Oct 2025 | Direct | F1, F9 |
| transaction | HALO | Common Stock | Sale | -$163K | -2.33K | -0.32% | $69.83 | 737K | 03 Oct 2025 | Direct | F1, F10 |
| transaction | HALO | Common Stock | Sale | -$191K | -2.71K | -0.37% | $70.58 | 734K | 03 Oct 2025 | Direct | F1, F11 |
| transaction | HALO | Common Stock | Sale | -$51.9K | -724 | -0.1% | $71.67 | 734K | 03 Oct 2025 | Direct | F1, F12 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HALO | Option to Purchase Common Stock | Options Exercise | -$162K | -20K | -14.64% | $8.11 | 117K | 01 Oct 2025 | Common Stock | 20K | $8.11 | Direct | F1, F13 |
| transaction | HALO | Option to Purchase Common Stock | Options Exercise | -$162K | -20K | -17.16% | $8.11 | 96.6K | 02 Oct 2025 | Common Stock | 20K | $8.11 | Direct | F1, F13 |
| transaction | HALO | Option to Purchase Common Stock | Options Exercise | -$162K | -20K | -20.71% | $8.11 | 76.6K | 03 Oct 2025 | Common Stock | 20K | $8.11 | Direct | F1, F13 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. |
| F2 | Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.44 to $75.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F3 | Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.445 to $76.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F4 | Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.83 to $70.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F5 | Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.83 to $71.81. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F6 | Represents a weighted average sales price per share. The shares were sold at prices ranging from $71.83 to $72.73. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F7 | Represents a weighted average sales price per share. The shares were sold at prices ranging from $72.96 to $73.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F8 | Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.65 to $74.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F9 | Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.05 to $68.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F10 | Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.172 to $70.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F11 | Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.172 to $71.106. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F12 | Represents a weighted average sales price per share. The shares were sold at prices ranging from $71.197 to $71.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F13 | Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016. |